no pathway map

News from the Bench

Discover what’s going on at CST, receive our latest application notes and tips, read our science features, and learn about our products.

Subscribe

Antibody Guarantee

CST Antibody Performance Guarantee

LEARN MORE  

To Purchase # 12121S

12121S 10 mg $179.00
$ 0. 00

Questions?

Find answers on our FAQs page.

ANSWERS  

Visit PhosphoSitePlus®

PTM information and tools available.

LEARN MORE

Western blot analysis of extracts from SK-BR-3 cells, untreated or treated with Lapatinib (6 hr) at the indicated concentrations, using Phospho-HER2/ErbB2 (Tyr1248)/EGFR (Tyr1173) Antibody #2244 (upper) or HER2/ErbB2 (D8F12) XP® Rabbit mAb #4290 (lower).

Learn more about how we got this image

Chemical structure of lapatinib.

Learn more about how we got this image
Image

Product Usage Information

Lapatinib is supplied as a lyophilized powder. For a 10 mM stock, reconstitute the 10 mg in 1.08 ml DMSO. Working concentrations and length of treatment can vary depending on the desired effect, but is typically used at 0.1-10 µM either as a pretreatment for 0.5-2 hr prior to treating with a stimulator or used alone with varying treatment times lasting up to 72 hr.


Storage: Store at -20°C.

Product Description

Molecular Weight:

925.46 g/mol


Purity:

>99%


Molecular Formula:

C29H26ClFN4O4S•2C7H8O3S


Lapatinib is a dual inhibitor of EGFR and HER2 tyrosine kinases (1-4). Researchers have shown that lapatinib inhibits purified EGFR and HER2 tyrosine kinase domains in cell-free kinase assays with IC50 values of 10.8 nM and 9.2 nM, respectively, and HER4 with an IC50 of 367 nM. Lapatinib was greater than 300-fold more selective for HER2 and EGFR than many other kinases, including c-src, MEK, Erk, and p38 in these assays (1). Studies have shown that lapatinib effectively inhibits both EGFR and HER2 autophosphorylation in cell types over expressing these kinases, and cell growth inhibition is correlated with HER2 overexpression (2-4).


1.  Rusnak, D.W. et al. (2001) Mol Cancer Ther 1, 85-94.

2.  Konecny, G.E. et al. (2006) Cancer Res 66, 1630-9.

3.  Zhang, D. et al. (2008) Mol Cancer Ther 7, 1846-50.

4.  Hegde, P.S. et al. (2007) Mol Cancer Ther 6, 1629-40.



For Research Use Only. Not For Use In Diagnostic Procedures.
Cell Signaling Technology® is a trademark of Cell Signaling Technology, Inc.